Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
12 března, 2021 6:34 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5509 Authors: Lukas Rob, Peter Mallmann, Pawel...
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study
12 března, 2021 6:31 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5501 Authors: Robert L. Coleman, Danielle Enserro,...
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
12 března, 2021 6:28 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5500 Authors: Takashi Onda, Toyomi Satoh, Toshiaki...
Správa z ASCO 2018 – Gynekologické malignity
12 března, 2021 6:25 pmAj keď sa tohtoročné ASCO nieslo v znamení noviniek a zmien v liečbe pediatrických, pľúcnych, prsníkových a pankreatických karcinómov, boli prezentované niektoré práce z gynekologickej...
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor- -positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
12 března, 2021 6:20 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer – Metastatic Abstract number: 1005 Authors: Guy Heinrich Maria...
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
12 března, 2021 6:13 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 501 Authors: Robert E. Coleman, Dianne Finkelstein,...
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
12 března, 2021 6:11 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 507 Authors: Valentina Guarneri, Maria Vittoria Dieci,...
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease- -free survival (DFS) results
12 března, 2021 6:08 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 506 Authors: Helena Margaret Earl, Louise Hiller,...
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
12 března, 2021 6:06 pmA 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months with chemotherapy, which is currently...
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
12 března, 2021 6:03 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: LBA1 Authors: Joseph A. Sparano, Robert James...